{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:39:43Z","timestamp":1758634783083},"reference-count":32,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2002,5,29]],"date-time":"2002-05-29T00:00:00Z","timestamp":1022630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2002,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We studied 15 patients with essential thrombocythemia (ET) before treatment and after normalization of platelet count by anagrelide. Significantly increased plasma levels of PDGF, TGF\u03b2, and bFGF were found. Patients with mild reticulin fibrosis in bone marrow had higher PDGF levels. During treatment, plasma TGF\u03b2 and bFGF levels remained elevated in most patients (<jats:italic>P<\/jats:italic> &lt; 0.0001 and <jats:italic>P<\/jats:italic> &lt; 0.01, respectively). Intraplatelet PDGF levels were low before treatment (<jats:italic>P<\/jats:italic> &lt; 0.006) and normal on hematological remission, without relation with the presence or absence of reticulin fibrosis in bone marrow. Intraplatelet TGF\u03b2 levels were normal regardless of the platelet count. Intraplatelet bFGF levels were raised before (<jats:italic>P<\/jats:italic> &lt; 0.001) and during treatment (<jats:italic>P<\/jats:italic> &lt; 0.01). By immunostaining, TGF\u03b2 and bFGF were seen in megakaryocytes and lymphocytes with a similar pattern of intensity in patients and controls, suggesting that other cells might also contribute to the raised plasma values. We believe that the plasma increment of these cytokines suggests that they play a role in the pathogenesis of ET. The normal PDGF plasma level found during treatment may be in relation with the platelet count. However, the persistent increase of TGF\u2010\u03b2 in plasma and bFGF both in plasma and platelets may indicate dysregulation of cytokine synthesis in TE. Am. J. Hematol. 70:85\u201391, 2002. \u00a9 2002 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.10091","type":"journal-article","created":{"date-parts":[[2002,10,6]],"date-time":"2002-10-06T12:35:39Z","timestamp":1033907739000},"page":"85-91","source":"Crossref","is-referenced-by-count":26,"title":["Variation of PDGF, TGF\u03b2, and bFGF levels in essential thrombocythemia patients treated with anagrelide"],"prefix":"10.1002","volume":"70","author":[{"given":"P.R.","family":"Lev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.F.","family":"Marta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Vassallu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.C.","family":"Molinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,5,29]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"29","article-title":"Experience of Polycythemia Vera Study Group With Essential Thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment","volume":"34","author":"Murphy S","year":"1997","journal-title":"Semin Hematol"},{"key":"e_1_2_1_3_2","first-page":"93","article-title":"Ultrastructure of the bone marrow tissue in so\u2010called primary (idiopathic) myelofibrosis\u2010osteomyelosclerosis (agnogenic myeloid metaplasia). 1. Abnormalities of megakaryopoiesis and thrombocytes","volume":"23","author":"Thiele J","year":"1991","journal-title":"J Submicrosc Cytol Pathol"},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1182\/blood.V57.4.781.781","article-title":"Human megakaryocyte stimulation of proliferation of bone marrow fibroblast","volume":"57","author":"Castro\u2010Malaspina H","year":"1981","journal-title":"Blood"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V74.7.2330.2330"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000205544"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb07952.x"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb08596.x"},{"key":"e_1_2_1_9_2","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood.V76.10.1946.1946","article-title":"Synthesis of transforming growth factor\u2010\u03b21 by megakaryocytes and its localization to megakaryocyte and platelet \u03b1 granules","volume":"76","author":"Fava RA","year":"1990","journal-title":"Blood"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04970.x"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/blood.V75.7.1540.1540","article-title":"The production of transforming growth factor\u2010\u03b2 in acute megakaryoblastic leukemia and its possible implications in myelofibrosis","volume":"75","author":"Terui T","year":"1990","journal-title":"Blood"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.12.4167"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.165.1.251"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.16.5788"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.140.8.2661"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb04310.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2470597"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1988.tb03160.x"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/S0021-9258(18)94267-5","article-title":"Independent regulation of collagenase, 72\u2010kDa progelatinase, and metalloendoproteinase inhibitor (TIMP) expression in human fibroblasts by transforming growth factor\u2010\u03b2","volume":"264","author":"Overal CM","year":"1989","journal-title":"J Biol Chem"},{"key":"e_1_2_1_20_2","first-page":"417","volume-title":"Biology of fibroblasts","author":"Jackson DS","year":"1973"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.3109\/08977199009043907"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2218497"},{"key":"e_1_2_1_23_2","first-page":"937","article-title":"Basic fibroblast growth factor and hematopoiesis","volume":"9","author":"Allouche M","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0955-2235(89)90012-4"},{"key":"e_1_2_1_25_2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1182\/blood.V81.3.631.631","article-title":"Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells","volume":"81","author":"Brunner G","year":"1993","journal-title":"Blood"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.292671.x"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830270409"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb04624.x"},{"key":"e_1_2_1_29_2","first-page":"1048","article-title":"Elevated plasma levels of basic fibroblast growth factor in patients with essential thrombocythemia and polycythaemia vera","volume":"98","author":"Wehmeier A","year":"1997","journal-title":"Br J Haematol"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3503164.x"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.8.1931.1931"},{"key":"e_1_2_1_32_2","first-page":"743a","article-title":"Differences in the species\u2010specific activity of anagrelide is mediated through the c\u2010mpl receptor (abstract)","volume":"96","author":"McCarty JM","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1986.tb05559.x"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.10091","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.10091","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T10:02:17Z","timestamp":1700301737000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.10091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5,29]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,6]]}},"alternative-id":["10.1002\/ajh.10091"],"URL":"https:\/\/doi.org\/10.1002\/ajh.10091","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,5,29]]}}}